1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
Gao S, Li N, Wang S, et al. Lung cancer in People's Republic of China. J Thorac Oncol, 2020, 15(10): 1567-1576.
|
3. |
Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365(5): 395-409.
|
4. |
Boiselle PM. Computed tomography screening for lung cancer. JAMA, 2013, 309(11): 1163-1170.
|
5. |
Heerink WJ, de Bock GH, de Jonge GJ, et al. Complication rates of CT-guided transthoracic lung biopsy: Meta-analysis. Eur Radiol, 2017, 27(1): 138-148.
|
6. |
Hofman P. Liquid biopsy and therapeutic targets: Present and future issues in thoracic oncology. Cancers (Basel), 2017, 9(11): 154.
|
7. |
Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. J Thorac Oncol, 2018, 13(9): 1248-1268.
|
8. |
Mateo J, Gerlinger M, Rodrigues DN, et al. The promise of circulating tumor cell analysis in cancer management. Genome Biol, 2014, 15(8): 448.
|
9. |
Calabuig-Fariñas S, Jantus-Lewintre E, Herreros-Pomares A, et al. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res, 2016, 5(5): 466-482.
|
10. |
Mayo-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, et al. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Rev Mol Diagn, 2018, 18(1): 35-45.
|
11. |
Shivange G, Urbanek K, Przanowski P, et al. A single-agent dual-specificity targeting of FOLR1 and DR5 as an effective strategy for ovarian cancer. Cancer Cell, 2018, 34(2): 331-345.
|
12. |
Chen X, Zhou F, Li X, et al. Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer. J Thorac Oncol, 2015, 10(8): 1163-1171.
|
13. |
Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol, 2020, 21(7): e342-e349.
|
14. |
Horeweg N, Scholten ET, de Jong PA, et al. Detection of lung cancer through low-dose CT screening (NELSON): A prespecified analysis of screening test performance and interval cancers. Lancet Oncol, 2014, 15(12): 1342-1350.
|
15. |
Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med, 1997, 157(8): 849-855.
|
16. |
Gould MK, Ananth L, Barnett PG, et al. A clinical model to estimate the pretest probability of lung cancer in patients with solitary pulmonary nodules. Chest, 2007, 131(2): 383-388.
|
17. |
McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med, 2013, 369(10): 910-919.
|
18. |
Hu B, Rochefort H, Goldkorn A. Circulating tumor cells in prostate cancer. Cancers (Basel), 2013, 5(4): 1676-1690.
|
19. |
Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev, 1989, 8(2): 98-101.
|
20. |
Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
|
21. |
Crosbie PA, Shah R, Summers Y, et al. Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. Transl Lung Cancer Res, 2013, 2(5): 382-397.
|
22. |
Wong SC, Chan CM, Ma BB, et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res, 2009, 15(3): 1005-1012.
|
23. |
Brown HK, Tellez-Gabriel M, Cartron PF, et al. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: Myth or reality? Drug Discov Today, 2019, 24(3): 763-772.
|
24. |
Hofman V, Heeke S, Marquette CH, et al. Circulating tumor cell detection in lung cancer: But to what end? Cancers (Basel), 2019, 11(2): 262.
|
25. |
Nunez MI, Behrens C, Woods DM, et al. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol, 2012, 7(5): 833-840.
|
26. |
Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem, 2005, 338(2): 284-293.
|
27. |
Lou J, Ben S, Yang G, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One, 2013, 8(12): e80458.
|
28. |
Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol, 2013, 6(6): 697-702.
|
29. |
Ning N, Zhan T, Zhang Y, et al. Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization. Clin Chim Acta, 2014, 433: 69-75.
|
30. |
Harper KL, Sosa MS, Entenberg D, et al. Mechanism of early dissemination and metastasis in Her2 + mammary cancer. Nature, 2016, 540(7634): 588-592.
|
31. |
Zhu WY, Alliegro MA, Melera PW. The rate of folate receptor alpha (FR alpha) synthesis in folate depleted CHL cells is regulated by a translational mechanism sensitive to media folate levels, while stable overexpression of its mRNA is mediated by gene amplification and an increase in transcript half-life. J Cell Biochem, 2001, 81(2): 205-219.
|
32. |
Ding C, Zhou X, Xu C, et al. Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma. Thorac Cancer, 2018, 9(11): 1413-1420.
|
33. |
Chang S, Hur JY, Choi YL, et al. Current status and future perspectives of liquid biopsy in non-small cell lung cancer. J Pathol Transl Med, 2020, 54(3): 204-212.
|
34. |
李媛秋, 么鸿雁. 肺癌主要危险因素的研究进展. 中国肿瘤, 2016, 25(10): 782-786.
|
35. |
Moon SM, Kim JH, Kim SK, et al. Clinical utility of combined circulating tumor cell and circulating tumor DNA assays for diagnosis of primary lung cancer. Anticancer Res, 2020, 40(6): 3435-3444.
|
36. |
Zhong CH, Tong D, Zhou ZQ, et al. Performance evaluation of detecting circulating tumor cells and tumor cells in bronchoalveolar lavage fluid in diagnosis of peripheral lung cancer. J Thorac Dis, 2018, 10(Suppl 7): S830-S837.
|
37. |
Dai F, Wang J, An H, et al. Therapy of 125 Ⅰparticles implantation inhibited the local growth of advanced non-small cell lung cancer: A retrospective clinical study. Am J Transl Res, 2019, 11(6): 3737-3749.
|
38. |
Zhou J, Diao X, Wang S, et al. Diagnosis value of combined detection of serum SF, CEA and CRP in non-small cell lung cancer. Cancer Manag Res, 2020, 12: 8813-8819.
|